SIGA Technologies (SIGA)
Market Price (12/30/2025): $6.25 | Market Cap: $447.5 MilSector: Health Care | Industry: Pharmaceuticals
SIGA Technologies (SIGA)
Market Price (12/30/2025): $6.25Market Cap: $447.5 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 17%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 13%, FCF Yield is 26% | Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -74% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -74% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% | Key risksSIGA key risks include [1] a substantial dependence on U.S. Show more. | |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 52% | ||
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 68%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 68% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics. Themes include Antiviral Drug Development, and Biodefense & Pandemic Preparedness. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 17%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 13%, FCF Yield is 26% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 52% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 68%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 68% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics. Themes include Antiviral Drug Development, and Biodefense & Pandemic Preparedness. |
| Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -74% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -74% |
| Key risksSIGA key risks include [1] a substantial dependence on U.S. Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Research findings questioning TPOXX efficacy for certain mpox strains.
News circulated around March 2025 indicated that the NIH found SIGA's tecovirimat (TPOXX) to be safe, but ineffective as a treatment for Clade II Mpox. Such findings regarding the efficacy of its primary product for specific variants of a target disease could lead to investor concern and a negative re-evaluation of the company's prospects.
2. Long-term investor profitability concerns.
As of November 24, 2025, reports indicated that the past three years had not been profitable for SIGA Technologies' investors. A prolonged period of unprofitable returns can lead to decreased investor confidence and selling pressure on the stock.
Show more
Stock Movement Drivers
Fundamental Drivers
The -30.2% change in SIGA stock from 9/29/2025 to 12/29/2025 was primarily driven by a -22.9% change in the company's P/E Multiple.| 9292025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 8.96 | 6.25 | -30.25% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 179.64 | 172.25 | -4.11% |
| Net Income Margin (%) | 45.75% | 43.23% | -5.49% |
| P/E Multiple | 7.79 | 6.01 | -22.87% |
| Shares Outstanding (Mil) | 71.47 | 71.60 | -0.20% |
| Cumulative Contribution | -30.25% |
Market Drivers
9/29/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| SIGA | -30.2% | |
| Market (SPY) | 3.6% | 15.9% |
| Sector (XLV) | 14.7% | 15.2% |
Fundamental Drivers
The -4.1% change in SIGA stock from 6/30/2025 to 12/29/2025 was primarily driven by a -37.4% change in the company's P/E Multiple.| 6302025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 6.52 | 6.25 | -4.14% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 120.33 | 172.25 | 43.15% |
| Net Income Margin (%) | 40.33% | 43.23% | 7.20% |
| P/E Multiple | 9.60 | 6.01 | -37.38% |
| Shares Outstanding (Mil) | 71.43 | 71.60 | -0.25% |
| Cumulative Contribution | -4.14% |
Market Drivers
6/30/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| SIGA | -4.1% | |
| Market (SPY) | 11.6% | 21.6% |
| Sector (XLV) | 16.1% | 5.4% |
Fundamental Drivers
The 16.4% change in SIGA stock from 12/29/2024 to 12/29/2025 was primarily driven by a 34.4% change in the company's P/E Multiple.| 12292024 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.37 | 6.25 | 16.39% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 173.73 | 172.25 | -0.85% |
| Net Income Margin (%) | 49.33% | 43.23% | -12.37% |
| P/E Multiple | 4.47 | 6.01 | 34.41% |
| Shares Outstanding (Mil) | 71.37 | 71.60 | -0.33% |
| Cumulative Contribution | 16.39% |
Market Drivers
12/29/2024 to 12/29/2025| Return | Correlation | |
|---|---|---|
| SIGA | 16.4% | |
| Market (SPY) | 16.6% | 25.5% |
| Sector (XLV) | 13.6% | 11.4% |
Fundamental Drivers
The 9.0% change in SIGA stock from 12/30/2022 to 12/29/2025 was primarily driven by a 54.9% change in the company's P/E Multiple.| 12302022 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.74 | 6.25 | 8.97% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 214.77 | 172.25 | -19.80% |
| Net Income Margin (%) | 50.25% | 43.23% | -13.96% |
| P/E Multiple | 3.88 | 6.01 | 54.86% |
| Shares Outstanding (Mil) | 73.02 | 71.60 | 1.94% |
| Cumulative Contribution | 8.93% |
Market Drivers
12/30/2023 to 12/29/2025| Return | Correlation | |
|---|---|---|
| SIGA | 32.3% | |
| Market (SPY) | 47.9% | 22.5% |
| Sector (XLV) | 17.6% | 12.8% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SIGA Return | 52% | 3% | 4% | -18% | 15% | 15% | 80% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 151% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| SIGA Win Rate | 58% | 50% | 33% | 50% | 58% | 58% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| SIGA Max Drawdown | -16% | -21% | -21% | -36% | -19% | -13% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/29/2025 (YTD)
How Low Can It Go
| Event | SIGA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -83.5% | -25.4% |
| % Gain to Breakeven | 505.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -26.9% | -33.9% |
| % Gain to Breakeven | 36.8% | 51.3% |
| Time to Breakeven | 29 days | 148 days |
| 2018 Correction | ||
| % Loss | -48.0% | -19.8% |
| % Gain to Breakeven | 92.2% | 24.7% |
| Time to Breakeven | 709 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -66.4% | -56.8% |
| % Gain to Breakeven | 197.9% | 131.3% |
| Time to Breakeven | 387 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
SIGA Technologies's stock fell -83.5% during the 2022 Inflation Shock from a high on 8/15/2022. A -83.5% loss requires a 505.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 brief analogies for SIGA Technologies:
- SIGA is like the Lockheed Martin for antiviral biodefense.
- SIGA is like Moderna for government biodefense stockpiles.
AI Analysis | Feedback
Here are SIGA Technologies' major products:- TPOXX (tecovirimat): An antiviral drug approved for the treatment of human smallpox disease caused by variola virus.
- Medical Countermeasures: Investigational drug candidates and advanced research to develop treatments for other public health threats, including chemical, biological, radiological, and nuclear (CBRN) agents.
AI Analysis | Feedback
SIGA Technologies (NASDAQ: SIGA) primarily sells its flagship product, TPOXX (tecovirimat), to governmental entities and healthcare providers, rather than to other publicly traded companies. Therefore, its major customers do not have public stock symbols.
SIGA's major customers include:
- U.S. Government: Specifically, the Biomedical Advanced Research and Development Authority (BARDA), an agency within the U.S. Department of Health and Human Services (HHS). BARDA contracts for the procurement of TPOXX for the U.S. Strategic National Stockpile. This is a governmental entity and does not have a public stock symbol.
- Canadian Government: Primarily the Department of National Defence, which procures TPOXX for its national preparedness programs. This is a governmental entity and does not have a public stock symbol.
- European Union: Through the European Health Emergency Preparedness and Response Authority (HERA), which procures TPOXX for strategic stockpiles within EU member states. This is a governmental/supranational entity and does not have a public stock symbol.
- Other International Governments: Various other sovereign nations that purchase TPOXX for their national medical countermeasure stockpiles. These are governmental entities and do not have public stock symbols.
- Hospitals and Healthcare Providers: For commercial sales of TPOXX for the treatment of diseases like monkeypox (MPOX) in countries where the drug is approved and commercially available. These are typically private, public, or non-profit institutions and do not have public stock symbols.
In summary, SIGA's major customers are not publicly traded companies with stock symbols, but rather governmental bodies and healthcare institutions.
AI Analysis | Feedback
nullAI Analysis | Feedback
Diem Nguyen, Ph.D., M.B.A. Chief Executive Officer
Diem Nguyen was appointed Chief Executive Officer and Director at SIGA in January 2024. She previously served as CEO of Xalud Therapeutics, a clinical-stage biotechnology company developing treatments for inflammatory diseases. Prior to Xalud, Dr. Nguyen was Executive Vice President of Biopharma at PPD Inc., a global clinical research organization. From 2009 to 2018, she held several leadership roles at Pfizer, including global president, Americas, Pfizer Essential Health, overseeing diverse commercial businesses with over $11 billion in annual revenue.
Daniel J. Luckshire, M.B.A. Executive Vice President and Chief Financial Officer
Daniel Luckshire has served as Executive Vice President and Chief Financial Officer since 2011. Before joining SIGA, he was a strategic advisor and private investor for various companies across specialized market segments. From 1998 to 2008, he held increasing positions of responsibility as an investment banker at Merrill Lynch & Co. Prior to Merrill Lynch, Mr. Luckshire was a member of the management team that built USI Insurance Services into a national insurance brokerage and was a CPA at Price Waterhouse LLP.
Dennis E. Hruby, Ph.D. Executive Vice President and Chief Scientific Officer
Dennis Hruby has served as Executive Vice President and Chief Scientific Officer since 2000. His earlier roles at SIGA included Vice President of Research from April 1997 to June 2000 and senior scientific advisor from January 1996 to March 1997. Dr. Hruby was also a faculty member at Oregon State University for 27 years, where he served as Director of the Molecular and Cellular Biology Program and Chairman of the Microbiology Department. He specializes in poxviruses, virology, and anti-infective research and holds approximately 200 U.S. and international patents.
Larry Miller General Counsel
Larry Miller has served as General Counsel for SIGA since March 2024. Before joining SIGA, Mr. Miller was General Counsel and Secretary at Phathom Pharmaceuticals, Inc. He previously served as General Counsel and Secretary at Blue Buffalo Company, where he advised the company through its $8 billion sale to General Mills.
Tove C. Bolken Senior Vice President, Operations and Chief Supply Chain Officer
Tove Bolken has served as Senior Vice President, Operations and Chief Supply Chain Officer since January 2020. She has been with SIGA since 1998, holding positions of increasing responsibility, including oversight of antiviral screening activities, drug development, and commercial manufacturing. Notably, she established an external manufacturing supply chain for SIGA’s smallpox antiviral product and has extensive government contracting experience, also serving as the company's corporate compliance officer.
AI Analysis | Feedback
The key risks to SIGA Technologies (NASDAQ: SIGA) primarily stem from its heavy reliance on government contracts and the performance of its lead product in securing expanded approvals and procurement.
- High Reliance on Government Contracts and Product-Specific Procurement Challenges: SIGA Technologies' revenue is substantially dependent on contracts with the U.S. government, notably through agencies like BARDA (Biomedical Advanced Research and Development Authority), for its primary product, TPOXX. The absence of new BARDA orders or delays in renewing existing contracts can significantly impact the company's financial results and stock valuation. Additionally, the company faces challenges in expanding its product's market; for instance, a clinical trial for TPOXX to treat Mpox failed to meet its primary endpoint, leading to a notable drop in stock price and raising concerns about future regulatory approvals and procurement for new indications.
- Revenue Volatility and Market Underperformance: SIGA's business model is characterized by inherent quarterly fluctuations in revenue, largely influenced by product delivery schedules and dynamic market conditions. This volatility has contributed to recent earnings declines and the company's stock underperforming both the broader US Pharmaceuticals industry and the overall market over the past year.
AI Analysis | Feedback
The primary emerging threat for SIGA Technologies is the anticipated slowdown in large-scale government procurement orders for TPOXX (tecovirimat).
SIGA's revenue is heavily reliant on government contracts for national stockpiles. Following a period of heightened demand driven by initial national stockpile build-up and increased awareness due to the global mpox outbreak, there is a clear risk that key customers may be nearing or reaching their desired inventory levels. This could lead to a sustained reduction in the frequency and/or size of new large contracts, transitioning from an accelerated procurement phase to a potentially slower, maintenance-driven market.
Evidence for this includes the company's own financial guidance, which often projects lower revenue in subsequent years compared to peak procurement periods, reflecting the inherent "lumpy" nature of government contracts and the potential for reduced demand post-initial stocking. For example, SIGA's 2024 revenue guidance of $100 million to $120 million is lower than its reported 2023 revenue of approximately $156 million, indicating an expected deceleration in procurement.
AI Analysis | Feedback
SIGA Technologies' primary product, Tpoxx (tecovirimat), targets the treatment of human smallpox disease and other orthopoxvirus infections like monkeypox, cowpox, and vaccinia complications.
Addressable Market Sizes for SIGA Technologies' Main Products:
Tpoxx (Tecovirimat) for Smallpox Treatment
- The global smallpox treatment market was valued at approximately USD 66.8 million in 2024 and is projected to reach about USD 78.27 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 2% during the forecast period.
- Another estimate indicates the global market for smallpox treatment was US$66.8 million in 2024 and is expected to reach US$73.7 million by 2030, with a CAGR of 1.6%.
- North America holds a significant share of this market, accounting for 47.6% of the global revenue in 2024. The U.S. market alone was valued at $18.1 million in 2024.
- The medication segment, which includes Tpoxx (tecovirimat), is anticipated to experience the fastest growth within the smallpox treatment market.
Tecovirimat (Tpoxx) for Orthopoxvirus Infections (including Smallpox and Monkeypox)
- The global Tecovirimat Monohydrate market, which encompasses treatments for orthopoxvirus infections, reached USD 428 million in 2024. It is projected to grow at a CAGR of 8.7% from 2025 to 2033, reaching an estimated value of USD 909 million by 2033.
- North America is expected to be a dominant region in the tecovirimat drugs market, driven by significant government stockpiling and a notable incidence of monkeypox infections.
Tpoxx (Tecovirimat) for Monkeypox Treatment
- The global monkeypox treatment market is forecast to reach approximately US$ 249 million by 2033, with demand increasing at a CAGR of 10.25% from 2023 to 2033.
- Another report estimates the global monkeypox treatment market size to exceed USD 211 million by 2033, growing at a CAGR of 11.20% from 2023 to 2033.
- Tecovirimat is projected to account for 61% of the market share by treatment type in the monkeypox treatment market by the end of the forecast period.
- North America is expected to lead the global monkeypox treatment market, potentially reaching a market share of around 48% by the end of the forecast period.
AI Analysis | Feedback
SIGA Technologies (SIGA) is poised for future revenue growth over the next 2-3 years, driven by several key strategic initiatives and market opportunities:
- Continued U.S. Government Procurement and Contracts: A primary driver of SIGA's revenue growth is its ongoing partnership with the U.S. government, particularly through contracts for TPOXX with the Strategic National Stockpile (SNS). The company reported significant procurement orders in Q3 2024, with substantial revenue recognition anticipated in Q4 2024 and 2025. A new potential long-term agreement with the U.S. Strategic Preparedness and Response (formerly BARDA) is also expected to be a major growth catalyst.
- International Market Expansion: SIGA is actively expanding the global reach of TPOXX through strategic partnerships. This includes successful sales in international markets, such as the first sale of oral TPOXX in Africa, and efforts to forge direct relationships with key international stakeholders. TPOXX is approved in various regions, including Europe, the UK, Canada, and Japan, providing a foundation for increased international sales.
- Advancing Regulatory Approvals for New TPOXX Indications and Formulations: The company is focused on securing regulatory approvals for new indications and formulations of TPOXX. Key targets include submissions for smallpox post-exposure prophylaxis (PEP) and a pediatric formulation. SIGA has already received development funding for pediatric formulation and IV tech transfer activities, underscoring this area as a growth avenue.
- Expansion into Complementary Therapeutic Areas and New Product Pipelines: SIGA plans to leverage its existing antiviral and government procurement capabilities to enter complementary therapeutic areas. Additionally, the company has broadened its product pipeline by acquiring an exclusive license for a portfolio of monoclonal antibodies from Vanderbilt University, aiming to develop new therapeutic options within the orthopox space. This diversification strategy is expected to contribute to future revenue growth.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years) for SIGA Technologies (SIGA)
Share Repurchases
- Since 2020, SIGA Technologies has returned approximately $230 million to shareholders through dividends and share buybacks.
- The company is committed to deploying capital for maximum value, including share repurchases, to drive shareholder value.
Share Issuance
- As of October 24, 2025, SIGA Technologies had 71,611,302 shares outstanding.
- As of September 30, 2025, 71,611,302 shares were issued and outstanding, an increase from 71,404,669 shares at December 31, 2024.
- In April 2025, the number of outstanding shares was 71,441,083.
Inbound Investments
- In June 2025, the BARDA 19C contract was modified to add $13 million in funding for SIGA's TPOXX pediatric development program.
- An additional $14 million in funding was added in April 2025 to support manufacturing activities under the BARDA 19C contract, bringing the total development funding added in Q2 2025 to $27 million.
- On March 26, 2025, an option for the procurement of $25.6 million of IV TPOXX was exercised by BARDA, increasing cumulative exercised options to $545.2 million.
Outbound Investments
- SIGA Technologies has made no investments or acquisitions to date.
Capital Expenditures
- In the last 12 months, capital expenditures for SIGA Technologies were -$332,308.
- For the nine months ended September 30, 2025, capital expenditures were ($314,470), compared to ($24,612) for the same period in 2024.
- The company purchased manufacturing equipment during Q3 2025.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| SIGA Technologies Earnings Notes | ||
| With SIGA Technologies Stock Surging, Have You Considered The Downside? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SIGA. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.4% | -9.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 17.0% | 17.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.1% | 3.1% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for SIGA Technologies
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.06 |
| Mkt Cap | 159.0 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 20.1% |
| Op Mgn 3Y Avg | 20.3% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 22.2% |
| CFO/Rev 3Y Avg | 23.8% |
| FCF/Rev LTM | 20.1% |
| FCF/Rev 3Y Avg | 21.6% |
Price Behavior
| Market Price | $6.25 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 09/10/1997 | |
| Distance from 52W High | -34.1% | |
| 50 Days | 200 Days | |
| DMA Price | $6.82 | $6.89 |
| DMA Trend | up | down |
| Distance from DMA | -8.3% | -9.3% |
| 3M | 1YR | |
| Volatility | 51.8% | 52.4% |
| Downside Capture | 89.01 | 72.38 |
| Upside Capture | -101.56 | 76.29 |
| Correlation (SPY) | 15.2% | 25.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.88 | 0.68 | 0.92 | 1.37 | 0.72 | 0.95 |
| Up Beta | 4.50 | 3.77 | 2.98 | 3.06 | 0.94 | 0.91 |
| Down Beta | 0.82 | 1.07 | 0.57 | 1.40 | 0.42 | 0.78 |
| Up Capture | -237% | -156% | -47% | 60% | 49% | 74% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 7 | 17 | 26 | 59 | 117 | 372 |
| Down Capture | 138% | 81% | 127% | 97% | 87% | 104% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 13 | 24 | 36 | 63 | 125 | 355 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of SIGA With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| SIGA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 16.2% | 13.8% | 16.7% | 65.4% | 7.5% | 4.2% | -7.3% |
| Annualized Volatility | 52.0% | 17.2% | 19.4% | 19.8% | 15.3% | 17.0% | 34.9% |
| Sharpe Ratio | 0.47 | 0.59 | 0.67 | 2.43 | 0.27 | 0.08 | -0.06 |
| Correlation With Other Assets | 11.5% | 25.7% | -1.8% | 6.9% | 10.9% | 21.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of SIGA With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| SIGA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 3.0% | 8.4% | 14.8% | 17.7% | 11.2% | 5.1% | 30.2% |
| Annualized Volatility | 68.8% | 14.5% | 17.1% | 15.6% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.33 | 0.40 | 0.70 | 0.91 | 0.48 | 0.18 | 0.57 |
| Correlation With Other Assets | 18.8% | 22.8% | 5.1% | 8.0% | 20.5% | 11.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of SIGA With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| SIGA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 15.3% | 10.1% | 15.0% | 14.6% | 6.9% | 5.4% | 69.0% |
| Annualized Volatility | 79.4% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.43 | 0.50 | 0.72 | 0.82 | 0.31 | 0.23 | 0.89 |
| Correlation With Other Assets | 15.2% | 17.5% | 2.1% | 6.7% | 15.2% | 6.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -20.0% | -25.6% | -23.5% |
| 8/5/2025 | 10.0% | 40.9% | 28.6% |
| 3/11/2025 | 7.0% | 2.9% | 8.7% |
| 11/7/2024 | -0.8% | -17.4% | -9.0% |
| 8/1/2024 | -5.8% | -0.6% | -2.3% |
| 3/12/2024 | 21.2% | 56.8% | 85.8% |
| 11/7/2023 | -6.6% | -4.3% | 14.1% |
| 8/8/2023 | -6.2% | -12.1% | -23.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 10 |
| # Negative | 7 | 8 | 8 |
| Median Positive | 10.0% | 11.2% | 10.3% |
| Median Negative | -5.8% | -10.3% | -11.2% |
| Max Positive | 21.2% | 56.8% | 85.8% |
| Max Negative | -20.0% | -25.6% | -25.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/05/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/08/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/11/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/07/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/01/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/07/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 03/12/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/07/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/08/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/04/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/02/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/03/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/04/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/05/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/03/2022 | 10-K (12/31/2021) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.